ZURICH, Sept 19 (Reuters) - Novartis (NOVN.VX: Quote, Profile, Research) said on Tuesday that its once-a-day Glivec pill had received additional EU approvals to help patients with two rare forms of cancer, including a rapidly progressive type of leukaemia.
